U.S. startups developing biomedical, healthcare, life-science and related technologies can pursue substantial non-dilutive capital through the NIH Parent Small Business Innovation Research programme.

The current Parent SBIR funding opportunity is PA-27-100, covering R43 and R44 awards and involving NIH, CDC and FDA components.

The September 2026 receipt date has passed, making January 5, 2027 the next standard submission opportunity, followed by April 5, 2027.

What Is NIH SBIR?

SBIR is part of America’s Seed Fund.

It uses federal research funding to help qualifying small businesses develop technically risky innovations with commercial potential.

Unlike venture capital, an SBIR grant does not require founders to sell ownership in the business.

The company can use federal R&D funding to create the evidence necessary for future commercialisation, partnerships or private investment.

How Much Funding Is Available?

The current general NIH guideline is $323,090 for Phase I and $2,153,927 for Phase II.

Individual NIH Institutes and Centers can allow higher budgets for approved waiver topics.

The amount a startup requests should therefore reflect the scientific work and the rules of the specific NIH institute that fits the project.

What Are Phase I and Phase II?

Phase I is designed to establish feasibility, technical merit and commercial potential.

The general project period can range from six months to two years.

Phase II supports continued research and development after the company reaches its Phase I milestones and can run for one to three years.

NIH also provides Fast-Track applications combining both phases, as well as Direct to Phase II for qualifying projects that have already demonstrated feasibility.

Who Can Apply?

The applicant must be an eligible U.S. small business concern.

The company must generally have no more than 500 employees and meet federal ownership and operating requirements.

Foreign companies cannot directly apply as the recipient organisation.

International founders should therefore examine the formal U.S. ownership and corporate-structure rules rather than assuming that simply registering a U.S. subsidiary is sufficient.

What Technologies Can Be Funded?

The parent programme spans the missions of many NIH institutes and participating CDC and FDA components.

Possible projects include drugs, biologics, medical devices, diagnostics, digital health, artificial intelligence, research tools, vaccines and other biomedical technologies.

The most important first step is matching the project with the right institute.

A cancer product, for example, may belong with NCI, while a neurological device could fit NINDS.

How to Build a Strong SBIR Application

An SBIR application is both a scientific proposal and a commercial-development case.

Founders should explain the research question, technical milestones, team, facilities and scientific approach.

They should also explain how successful research could eventually produce a product customers, hospitals, researchers, patients or other users will adopt.

Later-stage applications require more developed commercialisation planning.

Registration also takes time.

Applicants may need SAM.gov, Grants.gov, eRA Commons, SBA registration and related federal accounts before submission.

Official Funding Opportunity

Review NIH Parent SBIR PA-27-100

The current announcement expires in April 2027, so startups planning to apply should work backwards from the January or April receipt dates rather than beginning the process shortly before the deadline.